NBTX: מכפיל P/S עתידי Nanobiotix SA

סמל תאגידי ולוגו של Nanobiotix S.A. (NBTX)

Nanobiotix S.A. (NBTX) is developing NBTXR3 radio-enhancing particles to combat tumors, leveraging a strategic alliance with Janssen. Within the B2B ecosystem, the approval of nanomaterials is strictly regulated by the FDA and EMA. The company's forward P/S on the GURU.Markets daily chart reflects market expectations, where 159.20 serves as the current parameter value. Business success is predicated on clinical trial results and regulatory approvals.

NBTX Nanobiotix: יחס שווי שוק להכנסות עתידיות בטווח 04.07.2022 - 16.11.2026

פילוחי נתונים אנליטיים מרוכזים עבור nanobiotix.com (NBTX)

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח מקיף של החברה:NBTX (Nanobiotix S.A.)
מוצר מקורי של Nanobiotix S.A.

The innovative nanophysical oncology platform Nanobiotix S.A. requires specific capitalization monitoring via the future P/S multiple. This indicator compares the company's current market value with projected annual revenue to identify whether assets are overvalued or undervalued. The calculation is based on the ratio of the market price to the expected sales of the NBTXR3 product. The stability of this metric confirms market confidence in the long-term integration of the company's technologies into radiological protocols.